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ABSTRACT
Ruthenium complexes are considered as potential replacements for platinum 
compounds in oncotherapy. Their clinical development is handicapped by a lack 
of consensus on their mode of action. In this study, we identify three histones 
(H3.1, H2A, H2B) as possible targets for an anticancer redox organoruthenium 
compound (RDC11). Using purified histones, we confirmed an interaction between 
the ruthenium complex and histones that impacted on histone complex formation. 
A comparative study of the ruthenium complex versus cisplatin showed differential 
epigenetic modifications on histone H3 that correlated with differential expression 
of histone deacetylase (HDAC) genes. We then characterized the impact of these 
epigenetic modifications on signaling pathways employing a transcriptomic 
approach. Clustering analyses showed gene expression signatures specific for 
cisplatin (42%) and for the ruthenium complex (30%). Signaling pathway analyses 
pointed to specificities distinguishing the ruthenium complex from cisplatin. For 
instance, cisplatin triggered preferentially p53 and folate biosynthesis while the 
ruthenium complex induced endoplasmic reticulum stress and trans-sulfuration 
pathways. To further understand the role of HDACs in these regulations, we used 
suberanilohydroxamic acid (SAHA) and showed that it synergized with cisplatin 
cytotoxicity while antagonizing the ruthenium complex activity. This study provides 
critical information for the characterization of signaling pathways differentiating 
both compounds, in particular, by the identification of a non-DNA direct target for 
an organoruthenium complex.
INTRODUCTION
Transition metal complexes, including those of 
ruthenium, have been under investigation for several years 
as scaffolds for generating novel molecules harboring 
anticancer properties. These metals present interesting 
properties that confer advantages for designing cytotoxic 
compounds such as: enabling, otherwise inaccessible to 
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carbon-based chemistry, an octahedral geometry, a wide 
variety of redox potentials, accessibility of numerous 
oxidation states (I to IV) and interesting ligand exchange 
rates, enabling covalent interactions with biological 
macromolecules [1, 2]. In addition, ruthenium is 
hypothesized to be less toxic than platinum as it might 
be eliminated by iron metabolism mechanisms. A 
multitude of ligands have been used to produce various 
ruthenium complexes in the redox state (II) or (III). 
Most compounds are generated through complexation 
through a nitrogen atom of the ligand. Alternatively, 
organo-ruthenium compounds have been generated 
containing a covalent Ru-C bond (C, carbon) in the 
ligand. In vitro and in vivo biological studies established 
that several of these ruthenium-based compounds show 
high cytotoxicity towards a wide range of cancer cells 
and reduced side effects [1–12]. Gratifyingly, ruthenium-
based complexes are not affected by platinum-induced 
resistance mechanisms. Based on these characteristics, 
two ruthenium-based complexes, NAMI-A and KP1019, 
have been tested in phase I and II clinical trials [13, 14]. 
However, the lack of success of ruthenium compounds in 
late stage clinical trials may reside in part in the relative 
lack of understanding of their exact mode of action and the 
important chemical determinants involved.
In this respect, the mechanism of action of 
ruthenium-based complexes remains a matter of debate. 
Several modes of action have been proposed, which 
include interaction with DNA and activation of DNA 
damage pathways [15–19], kinase inhibition  [20] or 
other enzymatic activities [21, 22], including extracellular 
metallo-proteases [23], thioredoxin and cathepsin B [24] 
[25]. This variability may be due to differences in the 
structure of the ruthenium complexes, due to variations 
of the nature of the ligands as well as the type of bond 
linking the ligand to the ruthenium atom. In addition, no 
global approaches have been described so far that would 
give a more exhaustive and comprehensive understanding 
of the signaling pathways that are triggered in response to 
ruthenium-based compounds.
In this study, we have analyzed direct protein targets 
of RDC11 and changes in gene expression induced by this 
complex in comparison to the well-established anticancer 
metal-based drug cisplatin. RDC11 is an organo-ruthenium 
compound in which two acetonitriles, one phenanthroline, 
and one 2-phenylpyridine ligand are linked to the metal. The 
2-phenylpyridine is cyclometalated to the ruthenium, i.e. 
it is bound to Ru via the nitrogen’s lone pair and an ortho 
carbon atom of the phenyl unit. We previously demonstrated 
that RDC11 is highly cytotoxic (IC50 between 1–5 µM) on 
multiple cell lines including cisplatin resistant cells [18, 26]. 
Importantly, RDC11 reduces tumor growth in different 
models, including mouse syngeneic models (melanoma, lung 
cancer) and human xenografted models (glioma and ovarian 
cancer), with reduced toxicity towards healthy tissues 
compared to cisplatin [26, 27]. We have also previously 
shown that RDC11 and related compounds such as RDC34 
induce p53-dependent and Endoplasmic Reticulum (ER) 
stress pathways. However, we also showed that both 
pathways could not account for all the biological effect of 
RDC11-related compounds [18, 27, 28]. Finally, structure 
activity studies have indicated that RDC11 and RDC34’s 
cytotoxicity is at least partly related to their redox potential 
and the production of reactive oxygen species [26, 29].
To understand the mode of action of RDC11 we 
have used a proteomic approach identifying histones 
as potential proteins targeted by RDC11 and we have 
established the impact on the cellular transcriptome to 
identify novel signaling pathways that could elucidate 
the biological activity of RDC11. In addition, we have 
performed a comparative analysis with cisplatin in order 
to characterize specific signatures or similarities between 
cisplatin and our organoruthenium compound.
RESULTS
The cytotoxic organoruthenium complex RDC11 
interacts with histones in cancer cells
We previously showed that, although RDC11 
interacts with DNA, this does not fully explain its 
anticancer activity [26, 27, 30]. To identify RDC11’s 
putative protein targets we used an affinity chromatography 
approach in which RDC11 was covalently bound to a solid 
matrix (HypoGel 400-COOH) (Supplementary Figure S5). 
As a source of possible protein targets we used cell extracts 
of gastric cancer AGS cells. AGS cells are more sensitive to 
RDC11 than to cisplatin (Figure 1A, 1B). Before loading, 
AGS cell extracts were treated with DNAse to maximize 
the liberation of DNA bound proteins. After incubation of 
the AGS cell extract for 1 h with the RDC11-matrix, the 
matrix was washed several times with buffer of increasing 
salt concentration and then proteins were eluted with a 
solution of free RDC11. Eluted proteins were identified 
using mass-spectrometry. The experiment was repeated 
several times and the results were each time compared 
to proteins identified using only the naked matrix. Three 
histones, H3.1, H2A.1B and H2B.1K, and histone binding 
proteins, RBBP4 and RBBP7, were found repeatedly to 
bind to the RDC11-matrix (Figure 1C). Despite their small 
molecular weight, for each histone, several peptides were 
identified by mass-spectrometry. As histones are DNA 
binding proteins and we previously showed that RDC11 
binds to DNA, we decided to confirm that DNA did not 
mediate the interaction between RDC11 and histone. To 
do so, we used purified histones and incubated them with 
increasing amounts of RDC11. The mixture was then 
put to migration in a SDS-page under non-denaturing 
conditions (Figure 1D). Purified histones can migrate in 
non-denaturing gels as monomer, dimer and trimers. In 
the presence of RDC11, histone H3 migrated slower and 
with a more diffuse pattern suggesting the presence of 
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histones of higher molecular weight due to the binding of 
RDC11. Changes in histone migration were observed with 
histone monomers, dimers and trimers. The interaction of 
the ruthenium complex with histone was confirmed using 
histone immunoprecipitation experiments followed by 
quantification of ruthenium in the precipitates be ICP-MS 
(Supplementary data 3C). 
In cells, histones are the subject of multiple 
modifications that modulate their association with DNA, 
DNA compaction and also their translocation into the 
cytoplasm [31]. To assess the impact of RDC11-histone 
interactions in cells, we treated gastric cancer cells 
with RDC11 and extracted histones using two different 
protocols that allow either a preferential extraction of a 
soluble histone fraction (NP40 extraction buffer) or a full 
extraction of the histones bound to DNA (sample buffer) 
(Figure 1E). We observed that already, after three hours of 
treatment with RDC11 at the IC50 or the IC75 values, the 
Figure 1: (A) Schematic representation of cisplatin and RDC11. (B) Survival curve of cancer cells AGS treated with cisplatin or 
RDC11. Cells were treated for 48 hours in 96-well plates and their survival was evaluated by MTT assay (n = 8). (C) Table indicating the 
number of peptides of histones and histone related proteins present in the RDC11 affinity chromatography and mass spectrometric analysis 
of cell extracts. Repeats are the number of experiment with presence of the peptides out of three experiments done. (D) Migration of histone 
H3-RDC11 complex on non-denaturing SDS-Page. 100 ng of purified histone H3 was incubated with increased concentrations of RDC11 
(R 0.05 to 0.25 µM) for 1 hour. M is the molecular marker. Image is a silver stained gel of the complex showing the monomeric, dimeric 
and trimeric forms. (E) Proteins were extracted with the indicated buffer (NP40 or sample buffer) from AGS cells treated with RDC11 at 
the IC50 and the IC75 for 6 hours. Western blot analysis revealed histone H3 and actin protein levels.
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soluble fraction of histone H3 was significantly reduced. 
Altogether these results indicated that RDC11 can bind 
directly to histones and that this binding can impact on 
histone function in cancer cells.
Differential impact of RDC11 and cisplatin on 
histone modifications and epigenetic processes
As RDC11 binds to histones and diminishes the 
more soluble fraction of histone we hypothesized that it 
might impact on the post-translational modifications of 
histones. We analyzed, by Western-blot, the acetylation 
of histone H3 at lysine 9. We observed that histone H3 
acetylation was strongly increased by cisplatin and RDC11 
already 6 hours after treatment. However, after 24 hours 
there was a significant decrease of histone H3 acetylation 
under the RDC11 conditions while it remained elevated 
with cisplatin (Figure 2A). 
To further understand the impact of RDC11 and 
cisplatin on epigenetic regulations related to histones, 
we analyzed the expression of several genes encoding 
for enzymes involved in histone modifications. RT-qPCR 
experiments indicated that RDC11 and cisplatin regulated 
differently the expression of several histone deacetylases 
(HDAC) or other enzymes such as EZH2 (Figure 2B). In 
particular, the expression of HDAC4 was repressed by 
cisplatin and not affected by RDC11 while EZH2 was 
induced. In addition and conversely to HDAC4, HDAC9 
was induced by RDC11 and not by cisplatin. At the protein 
level, RDC11 induced HDAC4 at 6 hours while cisplatin 
already diminished its protein levels (Figure 2C). Finally, 
we used a xenografted tumor model to establish that the 
inhibition of HDAC4 expression was also observed in vivo 
(Figure 2D). 
The organoruthenium complex RDC11 presents 
a distinct transcriptomic signature 
The ability of RDC11 to interact directly with 
histones and its impact on histone post-translational 
modification through epigenetic regulation suggested that 
RDC11 might alter a broad range of signaling pathways. 
Hence, to identify without bias, RDC11 deregulated 
signaling pathways we performed a transcriptome analysis. 
In addition, to identify similarities and specificities in the 
gene regulations caused by ruthenium-based complexes 
versus platinum-based complexes, we treated cancer U87 
cells at the IC50 values for RDC11 (2 µM) and cisplatin 
(3 µM) (Supplementary Figure S3A). We chose these 
cells because the IC50 of the two drugs are close allowing 
us to identify gene regulations under similar treatment 
conditions. We also tested at two time points, 6 h and 
24 h, in order to identify early and later gene regulation 
events and their possible temporal and functional 
relationships. For the identification of regulated genes, we 
used Affymetrix hugene10stv1 arrays and each condition 
(Control: Ct; RDC11 6 h: R6; RDC11 24 h: R24; cisplatin 
6 h: C6; cisplatin 24 h, C24) was performed in triplicate.
Principal component analysis of the normalized 
data using RMA and probe-level linear models validated 
that the data are reproducible (Supplementary Figures 
S1A, S2, S3B). To detect differentially-expressed genes, 
we performed the comparative analysis between control 
and treated groups 6 hours and 24 hours after exposure. 
4540 probe sets with fold change ≥ ± 1.5 and adjusted 
p-value ≤ 0.05 were considered as significantly regulated 
in at least one comparative analysis. To find groups 
of genes with similar expression patterns across the 
different conditions and thus potentially involved in the 
same regulatory pathways, we performed hierarchical 
clustering analysis on the set of 4540 de-regulated probe-
set (Figure 3). Analysis of the 4540 genes revealed that 
922 probe-sets are de-regulated by cisplatin and 748 
probe-sets by RDC11 6 hours after exposure (Figure 4A, 
Supplementary Figure S1B). After 24 hours, 2910 and 
2314 probe-sets are regulated by cisplatin and RDC11 
respectively (Figure 4A). 22% to 28% (n = 207) of the 
probe-sets are regulated both by RDC11 and cisplatin 
6 hours after treatment. These numbers increase to 38% to 
48% (n = 1107) by 24 hours (Figure 4A). 
In our hands, several relevant groups of genes 
were deregulated. Differences in gene regulation are 
already detected 6 hours after exposure. For instance the 
cluster 10, 4 and 15 are made of genes downregulated 
after 6 hours of cisplatin treatment compared to control. 
Overall, the effect on gene regulation is greater after 24 
hours both in term of genes regulated and differences 
in gene expression levels (Figure 3). One group of 
genes (cluster 6, n = 776) is characterized by low/
moderate gene expression levels 6 hours after treatment 
with RDC11 or cisplatin, and high expression levels 
after 24 hours treatment. Gene set enrichment analysis 
revealed that this cluster is highly enriched for genes 
with functions in apoptosis (FDR < 10–5) such as 
p21, IRF1, NFKBIB, I-kB, ATF-3, PP2A regulatory, 
Caspase-7, C/EBP zeta, NF-kB, PPP2R5A, suggesting 
that apoptosis is induced by both chemicals after 
24 hours. In addition to this common set of genes, 
clustering revealed a specific group of genes induced 
either by RDC11 or cisplatin. For instance the cluster 8 
(n = 753), which is characterized by high expression 
levels 24 hours after cisplatin treatment, is enriched 
for genes in “apoptosis and survival Apoptotic 
Activin A” signaling (FDR < 10–3) such as Activin 
A, ActRIIA, Bcl-XL, p53, H-Ras, SHIP, c-Fos, 
while this pathway is not significantly regulated after 
24 h RDC11 treatment (R24). Cluster 7 (n = 409) 
is another example highlighting intrinsic differences 
in the transcriptional changes induced by RDC11 and 
cisplatin with a group of genes highly expressed in R24 
and with moderate or low expression levels in other 
conditions. Some effects of the cisplatin are mediated by 
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Figure 2: (A) Proteins were extracted from AGS treated with RDC11 (R6, R24) or cisplatin (C6, C24) for the indicated time 
(6 h, R6 and C6; 24 h, R24 and C24) using sample buffer. Western blot analysis revealed histone H3 acetyl lysine 7 (H3AK7), histone 
H3 (H3) and actin expression. Actin blot are shown in panel C. Quantifications of H3AK7/H3 are indicated below as measured by Pixi 
imager. (B) Curves are fold induction versus the control (Ct) for selected histone-modifying enzymes in RDC11 and cisplatin conditions. 
mRNA levels were assayed in AGS gastric cancer cells by RT-qPCR. Curves are means of fold induction versus the control (Ct) with SD 
(n = 3). *: p < 0.01.  (C) Proteins were extracted from AGS treated with RDC11 (R6, R24) or cisplatin (C6, C24) for the indicated time. 
Western blot analysis revealed EZH2, HDAC4, and actin expression. (D) mRNA levels of HDAC4 were assayed by RT-qPCR in fragments 
of human colon cancer xenografted in nude mice and after the treatment with cisplatin or RDC11. Graphs are means of fold induction versus 
the control (Ct) with SD (n = 5). *:p < 0.01.  
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specific down regulation of a set of 710 genes (cluster 10) 
enriched for function in cell adhesion via Ephrin 
signaling (FDR < 10–5) such Ephrin-A, Tiam1, FAP-
1, Ephrin-A5, Fyn, GRB10, Intersectin, VAV-2, NCK2 
(Grb4), FAK1 (Supplementary Table T1). Clustering into 
the different groups was confirmed by soft clustering 
(Supplementary Figure S1C) [32]. This, identifyies again 
a group of genes, soft cluster A, showing a moderate 
decrease in their expression at 6 hours, which is further 
downregulated at 24 hours of treatment with cisplatin or 
RDC11, respectively. Another example for the different 
effects of cisplatin and RDC11 on a group of genes is 
soft-cluster B, where cisplatin shows only a very low/
moderate effect on their expression, whereas this group 
of genes is strongly upregulated by RDC11 at 24 hours 
of treatment. Together, these data suggest that cisplatin 
and RDC11 share some mechanism activating apoptosis, 
but overall the mechanism of actions of these two drugs 
is distinct. Indeed, although the absolute number of 
genes regulated in common by both chemicals reached a 
maximum of 48% 24 hours after treatment (Figure 4A), 
the levels of regulation as well as the early and late 
responses are different, making the transcriptional imprint 
unique for each chemical in the conditions tested here. 
In order to assess a possible relative generalization 
of the findings to other cancer cell types and to validate 
some of the regulations observed using the arrays, we 
performed RT-qPCR analyses on U87 cells, HCT116 colon 
cancer cells and AGS gastric cancer cells. For this, several 
genes were chosen randomly and a representative set is 
shown in Supplementary Figures S3D and S4. Results 
were compared to the data obtained by the microarray 
analyses. In each cell line, drugs were applied at their IC50 
value for 6 or 24 hours. RT-qPCR experiments showed a 
good correlation with the results of the arrays for U87 or 
HCT116 cells. However, the correlation was not as strong 
for AGS cells, indicating that some of the mechanisms 
might be cell line-specific.
The organoruthenium complex RDC11 
modulates pathways distinct from cisplatin 
As indicated above, gene set enrichment analyses 
of different databases identified pathways commonly or 
Figure 3: Hierarchical clustering. Clustering of expression of 4540 probe-set significantly regulated in at least one treated group 
compared to control. Rows represent gene expression and columns biological samples. Gene expression levels are represented as scaled 
expression values (row Z-score from −3 to +3). Blue: low expression, Red: high expression, white: moderate expression. 17 different 
clusters are detected, indicated by their number and different color next the probe-set tree. C6: Cisplatin exposure for 6 hrs; C24: Cisplatin 
exposure for 24 hrs; R6: Ruthenium exposure for 6 hrs; R24:  Ruthenium exposure for 24 hrs.
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differently affected by RDC11 and cisplatin. Figure 4B 
shows the number of genes identified by gene set 
enrichment analyses that are upregulated in RDC11 
treated cells for the indicated pathway between 6 hours 
and 24 hours when compared to control conditions. As 
already seen in the clustering analyses (Figure 3), the 
overall regulations intensified with time, such as genes 
that are involved in apoptosis (i.e. APAF1, Caspase 3). 
In correlation with apoptosis-related genes, several genes 
involved in selected pro-apoptotic pathways, such as p53 
target genes, ER stress-related and oxidative stress-related 
genes are induced over time. Importantly, the expression 
of several genes of these pathways is already induced 
at 6 hours. In addition, genes involved in other cellular 
processes, such as several DNA damage-related genes, 
a few miRNAs, and multiple genes encoding enzymes 
involved in epigenetic control are upregulated over time 
by RDC11. 
Interestingly, when we compared the number of 
genes involved in these pathways and present at 24 hours in 
RDC11 or cisplatin-treated cells, several differences can be 
identified (Figure 4C). For example, p53-, DNA damage- and 
apoptosis-related genes are more present in cisplatin-treated 
cells. Inversely, ER stress- and oxidative stress-related 
genes are more frequent in RDC11-treated cells. Note that 
the number of miRNAs and epigenetic-related genes present 
in RDC11- and cisplatin-treated cells is similar. Strikingly, 
gene set enrichment analyses revealed that several cellular 
metabolic processes were very selectively regulated by 
either RDC11 or cisplatin (Figure 4D). For example, trans-
sulfuration and aminoacyl tRNA synthetase are selectively 
induced by RDC11. In contrast, genes involved in sterol 
Figure 4: Signaling pathways and mechanisms regulated by cisplatin or RDC11. (A) Venn diagram. Significantly deregulated 
probe sets between control and exposed conditions are compared to highlight genes shared or specific to each group. C6: Cisplatin exposure 
for 6 hrs; C24: Cisplatin exposure for 24 hrs; R6: Ruthenium exposure for 6 hrs; R24:  Ruthenium exposure for 24 hrs. (B, C, D) Graphs 
represents number of genes in the indicated pathways that are regulated by RDC11 at 6 hours or 24 hours (B) or by RDC11 and cisplatin 
at 24 hours (C, D). Microarray data were analyzed using AltAnalysis and R bioinformatics tools to identify in KEGG, Gene Ontology, 
miRNA, transcription factors databanks, the signaling pathways and mechanisms corresponding to the mis-regulated genes. 
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biosynthesis and sucrose metabolism are preferentially 
regulated in cisplatin-treated cells.
Altogether the gene set enrichment analyses 
indicated that RDC11 and cisplatin present each a 
preference in signaling pathways they regulate. These 
results clearly demonstrate that cisplatin and the 
ruthenium-based complex RDC11 have a different mode 
of action and point to some potential mechanisms that may 
account for the cytotoxicity of RDC11.
Cisplatin is a more potent inducer of the p53 
pathway than the organoruthenium complex 
RDC11 
To further validate some of the compound specific 
signatures identified by the gene set enrichment analyses, 
we performed RT-qPCR to measure the expression of p53 
target genes in HCT116. Cells were treated for 6 hours 
and 24 hours with cisplatin or RDC11 at their IC50. Gdf15, 
fas, bak1 and plk3 were all induced by cisplatin and 
RDC11 at 24 hours (Figure 5A, 5B, 5C, 5D). However, the 
induction by cisplatin was more pronounced and occurred 
often already at 6 hours of treatment. We then monitored 
the protein levels for p53 under the same experimental 
conditions. P53 proteins were significantly more abundant 
in cisplatin-treated cells compared to RDC11-treated cells 
(Figure 5E). In addition, increased p53 protein expression 
was already seen at 6 hours in cisplatin-treated cells. 
Although only weakly induced by RDC11, we assessed 
the importance of p53 in RDC11 biological activity 
using pifithrin, which is considered to be a p53 inhibitor 
[33]. Survival of cancer cells was assessed using MTT 
assays. Pifithrin did not block the biological activity of 
RDC11 except at doses above the IC75 values (75% of 
the maximal effect of RDC11, Figure 5F), while it had a 
significant effect on cisplatin cytotoxicity (Supplementary 
Figure 3E). The results indicated that RDC11 is less 
capable of inducing p53 signaling than cisplatin, but p53 
may still play a role in the biological activity of RDC11.
RDC11 is a more potent inducer of the ER 
pathway than cisplatin 
We also focused on the ER stress pathway, which 
represented a more selective signature for RDC11. RT-
qPCR showed that several genes, ditt3, atf4, chac1, 
dnajb2, involved in the ER stress pathway, were 
preferentially induced by RDC11 (Figure 6A, 6B, 6C, 6D). 
Some of these genes were also induced by cisplatin, but 
to a significantly lesser extent. To further document the 
induction of the ER stress pathway we analyzed the 
production of the spliced form of XBP1 (XBP1s). XBP1s 
is generated from IRE1 that is itself activated by the ER 
stress pathway. Figure 6E shows that RDC11 strongly 
induced the production of XBP1s while cisplatin had no 
or little effect. To assess whether eif-2a, a component 
of the ER stress pathway, is essential in the biological 
activity of RDC11 we used salubrinal, a known inhibitor 
of eif-2a [34]. Cell survival was assessed by a MTT assay 
and revealed that salubrinal did not significantly alter 
the cytotoxicity of RDC11 (Figure 6F). These results 
showed that although RDC11 stimulates preferentially the 
expression of components of the ER stress pathway, the 
activity of eif-2a is not required for RDC11 cytotoxicity.
An HDAC inhibitor antagonizes RDC11 activity 
but synergizes with cisplatin in gastric cancer 
cells
The gene set enrichment analyses also showed 
a strong deregulation of genes involved in epigenetic 
mechanisms (Figure 4B and 4C) confirming our previous 
observations on the effect of cisplatin and RDC11 on 
HDAC gene expression (Figure 2B, 2C, 2D).
To further assess the importance of HDAC 
regulation in cisplatin and RDC11 biological activity 
in cancer cells, we used the HDAC inhibitor SAHA 
(Vorinistat). MTT assays were first performed to establish 
the dose response curve of RDC11, cisplatin and SAHA in 
AGS cells (Figure 7A, 7B). In a second step, combination 
treatments were performed by combining the two drugs at 
specific concentrations (i.e. IC25, IC50) accordingly to the 
isobologram protocol [35]. The results were then analyzed 
using isobologram statistical analyses. This analysis, 
performed with different combinations of HDAC inhibitor 
and RDC11, showed an antagonistic effect of the HDAC 
inhibitor on the cytotoxicity of RDC11 (Figure 7D). In 
contrast, the HDAC inhibitor synergized with cisplatin’s 
cytotoxicity (Figure 7C). These results showed again 
a significant difference between the mode of action of 
RDC11 and cisplatin. In particular, this suggests that 
HDAC activity might be required for RDC11 cytotoxicity 
but not for cisplatin. 
To understand how SAHA might impact on RDC11 
biological activity, we analyzed the p53 and the UPR 
pathway. As previously observed, RDC11 induced p53 
and XBP1s protein levels as well as their target genes 
(Figure 7E, 7F, 7G, 7H). Interestingly, co-treatment with 
SAHA significantly diminished the impact of RDC11 on 
both signaling pathways. These series of results indicate 
that the epigenetic regulation controlled by RDC11 plays 
a role in RDC11 biological activity and changes the 
signaling pathways controlled by RDC11.
DISCUSSION
Nowadays, the precise identification of the mode of 
action of a drug destined for therapeutic purpose is crucial. 
In oncology, it allows the selection of the group of patients 
that have the best chance of responding to the treatment in 
an “a la carte” (personalized) therapeutic approach in which 
the mode of action of the drug matches the genetic profile 
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of specific tumors. It also provides markers to monitor the 
activity of the drugs during the therapy and point to the 
direction of a possible combination therapy by combining 
the compound with other therapeutic molecules. In addition, 
the identification of the direct target(s) is a clear advantage 
in developing a rational optimization process aiming at 
an improvement of the therapeutic activity. The general 
development of ruthenium-based anticancer compounds 
toward clinical use has been clearly handicapped by the 
lack of consensus about their mode of action and the long-
lasting misconception that ruthenium-based compounds 
represent a succedaneum of platinum-based compounds 
by acting via the same targets. To answer this complex 
problem we investigated the possible non-DNA direct 
targets of a ruthenium based complex (RDC11) and 
performed an unbiased transcriptomic approach to assess 
Figure 5: mRNA levels of gdf15 (A), fas (B), plk3 (C) and bak1 (D) were assayed in cancer cells by RT-qPCR. Curves 
are means of fold induction versus the control (Ct) with SD (n = 3). *:p < 0.01. (E) Proteins were extracted from cells treated with RDC11 
(R6, R24) or cisplatin (C6, C24) for the indicated time. Western blot analysis revealed p53 and actin expression. (F) Survival curve of AGS 
cells treated with RDC11 and pifithrin-α (10 µM). Cells were treated for 48 hours in 96-well plates and their survival was evaluated by 
MTT assay (n = 8).
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the repercussion of these interactions on cellular signaling 
pathways key for the control of cell survival. The results of 
this study provided a comprehensive view on how RDC11 
targets histones and illustrate its cellular consequences. In 
addition, the unbiased and global transcriptomic approach 
presented in this study provides an unique perspective 
on the respective characteristics of the organoruthenium 
compound RDC11 and cisplatin by providing information 
at two levels: i) a statistical evaluation of the difference and 
the similarities between the genes regulated by both drugs, 
ii) a list of novel genes, signaling pathways and metabolic 
processes regulated specifically by RDC11 that represents 
a source of information for pathways potentially regulated 
by other ruthenium-based compounds. Finally, this study 
Figure 6: mRNA levels of ddit3 (A), atf4 (B), chac1 (C) and dnajb2 (D) were assayed in cancer cells by RT-qPCR. Curves 
are means of fold induction versus the control (Ct) with SD (n = 3). *:p < 0.01. (E) Proteins were extracted from HCT116 treated with 
RDC11 (R6, R24) or cisplatin (C6, C24) for the indicated time. Western blot analysis revealed XBP1s and actin expression. (F) Survival 
curve of AGS cells treated with RDC11 and salubrinal (10 µM). Cells were treated for 48 hours in 96-well plates and their survival was 
evaluated by MTT assay (n = 8). Bars are means of fold induction versus the control (Ct) with SD (n = 3). *:p < 0.01.
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Figure 7: Survival curve of AGS cells treated with SAHA (A) and RDC11 (B). Cells were treated for 48 hours in 96-well 
plates and their survival was evaluated by MTT assay (n = 8). Bars are means of fold induction versus the control (Ct) with SD (n = 3). 
*p < 0.01. Isobologram analyses and combinatory index representations of combinatory treatments between cisplatin with SAHA (C) and 
RDC11 with SAHA (D). Doses at IC75, IC60, IC50, IC30, IC25 were combined and the results were analyzed with the algorithm of Chu and al. 
using the CompuSyn software. (E, G) Proteins were extracted from cancer cells treated with RDC11 (R24) or SAHA (S24) or RDC11 and 
SAHA (R = S) after 24 hours of treatment. Western blot analysis revealed p53 (E) and XBP1s (G) and actin expression. Quantifications are 
indicated below as measured by Pixi imager. (F, H). mRNA levels of p53 (A), noxa (B), ddit3 (C) and chac1 (D) were assayed in cancer 
cells by RT-qPCR. Graphs are means of fold induction versus the control (Ct) with SD (n = 3). *p < 0.01. (E) Proteins were extracted from 
cells treated with RDC11 (R24) or SAHA (S24) or RDC11 and SAHA (R+S) for the 24 hours.
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illustrates also how such information may provide hints 
for developing novel combination treatments. In this 
present case, we focused on histone deacetylase (HDAC) 
regulation.
An organoruthenium compound interacts with 
histones
Our study shows that the organoruthenium 
compound RDC11 interacts with several histones (H3, 
H2A and H2B) in cells (Figure 1C) and in vitro with 
purified histones (Figure 1D). This finding represents 
one of the very few examples of a non-DNA target for 
ruthenium complexes that has been validated using cellular 
extract. The ability of RDC11 to interact with purified 
histones suggests strongly that the interaction is direct. 
In addition, the fact that the interaction is still observed 
after several washes or in a polyacrylamide gel also 
indicates that the interaction is relatively stable. It remains 
to be established more precisely how the compound 
interacts with histones, such as whether it involves 
specific interactions and how it affects the proteins at 
the molecular and structural level. The migration pattern 
of the RDC11/histone complex shows a tendency of 
increased trimeric forms, suggesting that the interaction 
between RDC11 and histone may favor formation of 
histone complexes (Figure 1D). This is also supported by 
the fact that using different protein extraction buffers, we 
observed that treatment of the cells with RDC11 leads to 
a decrease in the more soluble fraction of histones in the 
cells (Figure 1E). This set of results supports a preceding 
finding that a ruthenium complex of piano stool structure 
called READ-C interacts with histones [36]. In addition, 
our study is the first demonstration of an organoruthenium 
compounds that interact with histone in cells and it also 
shows that ruthenium compounds have an impact on 
the post-translational modifications of histones. These 
modifications are part of complex and essential epigenetic 
mechanisms that are essential and complex control of gene 
expression [31].
An organoruthenium compound impacts on 
epigenetic regulations
It is expected that the interaction between a 
ruthenium compound and histones may alter the 
complexes in which histones are involved: DNA/histones 
and histones/epigenetic enzymes modifying histones, 
Indeed, we observed that, in cells treated with RDC11 
histones have a different solubility and post-translational 
modification pattern. For instance, histone H3 levels are 
lower in the more soluble fraction and its acetylation 
on lysine 9 is increased (Figure 2). Interestingly, the 
acetylation pattern is different between RDC11 and 
cisplatin. It remains to be established whether the 
modification of solubility and acetylation is directly due 
to the binding of RDC11 to histone H3. Addressing this 
specific point represents a complex technical challenge.
Similarly, understanding precisely the relationship 
between the interaction of RDC11/histones and the 
transcriptional regulation affecting the epigenetic enzymes 
will be also challenging. Indeed, if RDC11 alters the 
expression of HDAC and demethylases (Figures 2B–2D, 
4B–4C), we still need to assess whether these are 
adaptation/compensation mechanisms of the chromatin 
to the structural perturbation due to RDC11 binding, 
or whether it is a consequence of the modification of 
chromatin structure leading to different accessibility 
to transcription factors. Indeed, RDC11 treated cells 
show a change in the expression of several HDACs and 
other epigenetic modifiers. These changes are different 
to those induced by cisplatin. For instance, HDAC4 is 
strongly repressed by cisplatin whereas RDC11 induced 
significantly HDAC9. These changes already happen 
6 hours after treatment suggesting that they participate 
into the gene expression regulation observed in cancer 
cells. The fact that these changes are also observed 
in vivo (Figure 2D) further support their importance 
for RDC11 and cisplatin’s biological and anticancer 
activity. To elucidate the impact on gene expression of 
these epigenetic modifications induced by RDC11 and/or 
cisplatin transcriptomic data were analyzed.
Specificities in RDC11 and cisplatin 
transcriptomic profiles
Bio-statistical analyses of the microarray data 
showed significant differences in the number and quality 
of the genes regulated by RDC11 or cisplatin. Among the 
4540 genes that we identified to be regulated, less than a 
third were common to RDC11 and cisplatin (Figures 3, 4). 
About 40% were specifically regulated by cisplatin and 
a third by RDC11. This difference is even more marked 
at 6 hours post-treatment, as only 1.5% of the regulated 
genes are common between cisplatin and RDC11-
treated cells. The clustering analyses further highlighted 
the existence of 17 gene clusters that show significant 
variation of the expression profile over time between 
RDC11 and cisplatin after treatment (Figures 3, 4). The 
significant differences in the transcriptome controlled by 
RDC11 and cisplatin indicate that both compounds should 
trigger different signaling pathways, likely reflecting 
distinctive mode of actions. 
A more detailed analysis of the signaling pathways 
or cellular mechanisms that are controlled by the regulated 
genes confirmed the existence of common and distinctive 
effects between RDC11 and cisplatin. Apoptosis, DNA 
damage, p53, epigenetic, miRNA, ER stress and oxidative 
stress were amongst the mechanisms that were regulated 
by both drugs (Figures 4, 5, 6). However, the number 
and the intensity of activation of the genes included in 
those pathways were often significantly different between 
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RDC11 and cisplatin. For example, cisplatin induces a 
high number of genes involved in DNA damage, p53, and 
apoptosis, while RDC11 favors oxidative- and ER stress-
related genes. The differences between both drugs are 
even more accentuated on specific metabolic pathways 
(Figure 4D). For example, RDC11 specifically regulates 
ribosome biogenesis, while cisplatin favors sucrose 
metabolism.
Respective contribution of the p53 and ER stress 
pathway in RDC11 activity
Some of these specificities were previously 
documented by our group, such as the preferential activation 
of the p53 pathway by cisplatin or the ER stress pathway 
by RDC11 in glioblastoma cells [26, 27, 30]. Here, we 
further extended these observations by showing that these 
specificities are common to cancer cells of different origin, 
such as colon cancer cells (HCT116) or gastric cancer cells 
(AGS). In addition, we extended the observation to an 
additional pool of genes and to the protein level for a marker 
of the ER stress pathway (Figures 5, 6, 7). Altogether, these 
novel observations validate the preferential activation of 
the ER stress pathway by RDC11 in different cancer cell 
lines. With the endoplasmic reticulum being also the place 
of protein translation, it is interesting to note that RDC11 
triggered a ribosomal biogenesis response along with the 
ER stress pathway (Figure 4).
Interestingly, the preferential activation of the 
p53 pathway by cisplatin correlates with a preferential 
activation of DNA damage response. Hence, compared 
to RDC11, cisplatin appears to induce a coherent DNA-
damage/p53 pathway response, which is also consistent 
with the preferential binding of cisplatin to DNA as 
compared to RDC11 [26, 27, 30]. We previously described 
this pathway to contribute to the neurotoxic activity of 
cisplatin [37, 38].
The exact contribution of the p53 pathway and the 
ER stress pathways in RDC11 activity have already been 
investigated previously in glioblastoma cells. Using a 
dominant inhibitor and p53-/- cell lines, we previously 
showed that p53 is not absolutely necessary for RDC11 
cytotoxicity [26, 27]. We confirmed here these results 
by showing the RDC11 induces less the p53 pathways 
compared to cisplatin and that a known inhibitor of 
p53 (pifithrin) does not drastically alter the activity of 
RDC11. We also inhibited eIE2a, a component of the 
ER stress pathway, with salubrinal, which did not alter 
RDC11 cytotoxicity. This result apparently contradicts 
previous data showing that the ER stress transcription 
factor CHOP is partly necessary for RDC11's full 
cytotoxicity [27]. This apparent contradiction highlights 
the complexity of the ER stress pathway and might be 
explained by the fact that the activation of eIE2a by 
PERK represents only a part of the mechanisms triggered 
by the ER stress pathway [39]. For example, CHOP can 
be induced by other mechanisms related to the ER stress 
pathway, such as ATF6.
Respective role of epigenetic regulators in 
RDC11 and cisplatin cytotoxicity
Amongst the mechanisms that were regulated 
differently by RDC11 and cisplatin, several genes 
encoding for histones and histone-modifying enzymes 
were included. These genes and in particular HDACs, are 
playing a critical role in various biological process and 
represent interesting therapeutic targets [40]. Our study 
showed that whereas EZH2 was induced by both RDC11 
and cisplatin, HDAC4 was preferentially repressed 
by cisplatin. This repression of HDAC4 by cisplatin 
was also observed in vivo in fragments of human colon 
cancer xenografted in nude mice (Figure 2D). In addition, 
we observed that these gene regulations impact on the 
acetylation of histone H3 at lysine 9 in a time- and drug-
dependent manner. In particular, 6 hours after treatment, 
RDC11 represses H3 acetylation while cisplatin already 
induces it. Such differential drug response correlates with 
a profound difference in the impact of HDAC inhibitors on 
RDC11 and cisplatin's biological activity. Indeed, a known 
HDAC inhibitor, SAHA, had a synergistic anticancer 
activity with cisplatin in AGS human gastric cancer cells 
as previously observed by others with cancer cell lines of a 
different origin [41]. In contrast, we demonstrate here that 
an HDAC inhibitor (SAHA) inhibits RDC11 biological 
activity as revealed by the antagonistic effect observed 
in the isobologram analysis. This result suggests that, in 
contrast to cisplatin, RDC11’s biological activity might 
require the activity of some HDACs by modifying either 
the histones or some of their other targets. From a more 
therapeutic point of view, this study indicates that RDC11 
is not a good candidate to be used in combinatory therapy 
with general HDAC inhibitors for it might depend on the 
expression and/or activity of HDACs in the tumor. It also 
confirms the potential advantage of combining HDAC 
inhibitors with platinum-based therapies in gastric cancers. 
From a more mechanistic point of view, we also 
show that the combination of RDC11 with SAHA impact 
on the signaling pathways regulated by RDC11. The 
induction of p53 and Noxa is almost annihilated by SAHA 
when combined with RDC11. Similarly, SAHA reduced 
XBP1's? signaling (Figure 7). These changes in signaling 
may account for the differential biological activity of 
RDC11 in the presence of SAHA.
Overall this study demonstrates that RDC11 and 
cisplatin have different modes of action and trigger the 
regulation of different signaling pathways. Whereas both 
agents lead to regulation of pro-apoptotic effectors and cell 
cycle inhibitors, the intermediate mechanisms are quite 
different. These differences have profound consequences 
as they will define how we might use RDC11 on tumors 
with specific signatures (i.e. p53 mutated or not) or with 
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specific other therapeutic molecules. It remains for us 
to establish how these findings can be generalized to 
other ruthenium-based compounds or even other metal-
based compounds. Our previous studies, as well as 
those of others, showing that ruthenium- or osmium-
based compounds with different ligands trigger similar 
regulation of p53 and ER-stress pathways, suggest that the 
findings of this study might point out potential signaling 
pathways targeted by other metal-based compounds [26] 
[19, 20, 42, 43]. 
MATERIALS AND METHODS
Chemicals and purified proteins
Cisplatin, pifithrin, SAHA and salubrinal were 
purchased from Sigma and used as received. RDC11 was 
synthesized and purified as previously described [18]. 
DNA-free purified histones were purchased from New 
England Biolabs. 
Cell cultures
U87, AGS and HCT116 cells were obtained 
from ATCC. Cells were manipulated and cultured in 
DMEM with 10% FCS (Dominique DutcherTM) and 
1% Penicillin + Streptomycin (Sigma) at 37°C with 
5% CO2 atmosphere as previously described [44]. 
All experiments were conducted by comparing the 
treatments with cells treated with buffer without the 
active compounds (cisplatin, ruthenium complex or 
SAHA).
Cell survival assay
2000 cells were seeded per well in 96-well 
microplates (Falcon Multiwell), 48 h prior to any 
treatment. Cisplatin and RDC11 were applied for 48 h in 
fresh medium. MTT assay was performed as previously 
described by replacing the medium with fresh medium 
supplemented with 5 mg/L MTT (Sigma) for 1 h [45]. 
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Cells were lysed in isopropanol with 0.04 N HCl. 
Measurements were performed at 550 nm.
Quantitative PCR
Cultured cells were lysed with 1ml of TRIzol 
(Invitrogen) per 10x106 cells and RNA extracted 
according to the manufacturer’s instructions. RNA 
samples were ethanol-precipitated twice and 1 µg was 
used for reverse transcription (High-Capacity cDNA 
Reverse Transcription Kit, Applied Biosystems). 
RNA quality was assessed by qPCR was performed 
using 2 ng/µl cDNA (RNA equivalent) according to 
the manufacturer’s instructions (SYBR Green PCR 
Master Mix, Applied Biosystems) and with 400 µM of 
each primer (Supplemental data, Table 1). The relative 
expression was calculated using the ΔΔCt method. 
Expression levels were normalized using average of 
18 S or TBP.
Statistical analysis
Statistical analyses were performed using a one-
way ANOVA test followed by a Tukey pos t-test allowing 
a comparison between all the conditions. * Indicate 
statistical differences in graphs. Statistical Analyses were 
performed using Prism (GraphPad software).
Western blotting
Cells or tissue were lysed with LB (125mM Tris-
HCl pH 6.7, NaCl 150 mM, NP40 0.5%, 10% Glycerol). 
Proteins (20 µg) were denatured and deposited directly 
(75 µg of proteins) onto a SDS-PAGE gel. Western 
blotting was performed using antibodies raised against p53 
(rabbit anti-p53, FL-393, Santa Cruz, CA), XBP1s (Santa 
Cruz, CA), EZH2 (Cell Signaling), H3 (Cell Signaling), 
H3K9 (Abcam) and HDAC4 (Biolegend). Secondary 
antibodies (anti-rabbit, anti-mouse: Sigma, MA) were 
incubated at 1:1000. Loading was controlled with actin 
(rabbit anti- β-actin, Sigma, 1:4000) [46].
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